332099-38-4

Usage

InChI:InChI=1/C9H8ClNO3/c1-2-13-9(12)6-3-7-5(11-6)4-8(10)14-7/h3-4,11H,2H2,1H3

Upstream product

• 7283-96-7 5-Chloro-2-thiophenecarboxaldehyde 
• 681486-10-2 (Z)-2-Azido-3-(5-chloro-thiophen-2-yl)-acrylic acid ethyl ester 

Downstream Products

• 332099-40-8 2-chloro-4H-thieno[3,2-b]pyrrole-5-carboxylic acid 
• 1333498-57-9 diethyl 2-chloro-6-(4-methoxybenzoyl)-4H-thieno[3,2-b]-pyrrole-4,5-dicarboxylate 
• 1333498-58-0 ethyl 2-(2-chloro-5-ethyloxycarbonyl-6-(4-methoxybenzoyl)-4H-thieno[3,2-b]pyrrol-4-yl)acetate 
• 1333498-59-1 ethyl 2-chloro-4-allyl-6-(4-methoxybenzoyl)-4H-thieno[3,2-b]pyrrole-5-carboxylate 
• 1333498-60-4 5-ethyl 4-benzyl 2-chloro-6-(4-methoxybenzoyl)-4H-thieno[3,2-b]pyrrole-4,5-dicarboxylate 
• 1333498-56-8 ethyl 2-chloro-6-(4-methoxybenzoyl)-4H-thieno[3,2-b]pyrrole-5-carboxylate 

Relevant academic research and scientific papers

Synthesis and antimicrobial activity of ethyl-2-chloro-4-substituted 6-(4-Methoxybenzoyl)-4H-thieno[3,2-b]pyrrole-5-carboxylates

Ethyl-2-chloro-6-(4-methoxybenzoyl)-4H-thieno[2,3-b]pyrrole-5-carboxylate (3) has been prepared by refluxing a mixture of 2-chlorothieno[2,3-b]pyrrole-5- carboxylate, 4-methoxy benzoylchloride and TiCl4 in dichloromethane. Ethyl-2-chloro-4-substituted 6-(

Synthesis and CHK1 inhibitory potency of Hymenialdisine analogues

A series of thieno[3,2-b]pyrroloazepinones derivatives related to Hymenialdisine were prepared and tested for CHK1 inhibitory activity. Nanomolar inhibitions were achieved when electron-withdrawing substituents were introduced at position 3 of the thiophene ring.

The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors

The 'NMDA hypofunction hypothesis of schizophrenia' can be tested in a number of ways. DAO is the enzyme primarily responsible for the metabolism of d-serine, a co-agonist for the NMDA receptor. We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats. In parallel, analogues were prepared to survey the SARs of 1.

Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: Potent human histamine H4 antagonists

Three series of H4 receptor ligands,- derived from indoly-2-yl-(4-methyl-piperazin-1-yl)-methanones, have been synthesized and their structure-activity relationships evaluated for activity at the H 4 receptor in competitive binding and functional assays. In all cases, substitution of small lipophilic groups in the 4 and 5-positions led to increased activity in a [3H]histamine radiolabeled ligand competitive binding assay. In vitro metabolism and initial pharmacokinetic studies were performed on selected compounds leading to the identification of indole 8 and benzimidazole 40 as potent H4 antagonists with the potential for further development. In addition, both 8 and 40 demonstrated efficacy in in vitro mast cell and eosinophil chemotaxis assays.

Heterocyclic compounds

Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H4 receptor, including allergic rhinitis.

Synthesis and biological evaluation of thiophene [3,2-b] pyrrole derivatives as potential anti-inflammatory agents

A series of thiophene [3,2-b] pyrrole derivatives were synthesized and evaluated their abilities to inhibit anti-inflammatory activity. In this series, substituent effects at the N-1, 2 and 5 positions of thiophene [3,2-b] pyrrole were examined. The results obtained are compared to those previously reported anti-inflammatory drugs like Tenidap sodium, Diclofenac sodium and Piroxicam. The results indicated the critical role of the group linked in the N-1 position and 2, 5 positions of thiophene [3,2-b] pyrrole with different functional groups.

Use of glycogen phosphorylase inhibitors

The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors

This invention relates to compounds of Formula I or stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or a pharmaceutically acceptable salts of the prodrugs. This invention also relates to pharmaceutical compositions comprising a compou